## William A Hal

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/965490/publications.pdf

Version: 2024-02-01

101 papers 2,525 citations

30 h-index 233421 45 g-index

102 all docs 102 docs citations

102 times ranked 3695 citing authors

#	Article	IF	Citations
1	Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians. Ca-A Cancer Journal for Clinicians, 2022, 72, 34-56.	329.8	45
2	Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. International Journal of Radiation Oncology Biology Physics, 2022, 112, 83-92.	0.8	6
3	Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer. Journal of Gastrointestinal Oncology, 2022, 13, 185-196.	1.4	1
4	General and custom deep learning autosegmentation models for organs in head and neck, abdomen, and male pelvis. Medical Physics, 2022, 49, 1686-1700.	3.0	16
5	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.6	10
6	Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer Journal of Clinical Oncology, 2022, 40, 589-589.	1.6	1
7	Survival outcome and treatment response of patients with young-onset locally advanced rectal cancer (YO-LARC) receiving total neoadjuvant therapy (TNT) Journal of Clinical Oncology, 2022, 40, 44-44.	1.6	1
8	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study Journal of Clinical Oncology, 2022, 40, 474-474.	1.6	0
9	A prospective observational study to determine the feasibility of tumor response assessment by circulating tumor DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) undergoing total neoadjuvant therapy (TNT) Journal of Clinical Oncology, 2022, 40, TPS234-TPS234.	1.6	0
10	Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response Journal of Clinical Oncology, 2022, 40, 596-596.	1.6	0
11	A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study Journal of Clinical Oncology, 2022, 40, TPS220-TPS220.	1.6	0
12	Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac. Acta Oncol $\tilde{A}^3$ gica, 2022, 61, 111-115.	1.8	26
13	First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Technical Innovations and Patient Support in Radiation Oncology, 2022, 22, 50-54.	1.9	7
14	Adaptive Radiation Therapy Physician Guidelines: Recommendations From an Expert Users' Panel. Practical Radiation Oncology, 2022, 12, e355-e362.	2.1	8
15	The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	2
16	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. Journal of Clinical Oncology, 2022, 40, 3172-3179.	1.6	14
17	MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i> -mutated advanced pancreatic ductal adenocarcinoma (PDAC) Journal of Clinical Oncology, 2022, 40, e16260-e16260.	1.6	2
18	Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer Journal of Clinical Oncology, 2022, 40, e16281-e16281.	1.6	0

#	Article	IF	Citations
19	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study Journal of Clinical Oncology, 2022, 40, TPS4618-TPS4618.	1.6	1
20	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.8	77
21	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 2246-2256.	1.5	29
22	Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery, 2021, 169, 629-635.	1.9	2
23	Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncology, The, 2021, 22, 11-13.	10.7	23
24	Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. Practical Radiation Oncology, 2021, 11, 527-533.	2.1	3
25	The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?. Clinical and Translational Radiation Oncology, 2021, 28, 124-128.	1.7	4
26	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Frontiers in Oncology, 2021, 11, 628155.	2.8	27
27	Early Comparative Toxicity Outcomes of Patients With Prostate Cancer Receiving Initial Cryotherapy and Radiotherapy Salvage. Clinical Genitourinary Cancer, 2021, 19, 267-270.e1.	1.9	2
28	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. American Journal of Surgery, 2021, 222, 10-17.	1.8	41
29	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. International Journal of Radiation Oncology Biology Physics, 2021, 111, 867-875.	0.8	37
30	Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group. European Journal of Cancer, 2021, 153, 64-71.	2.8	21
31	Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 719-730.	1.5	4
32	Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. Cancers, 2021, 13, 5204.	3.7	13
33	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Cancer and Metastasis Reviews, 2021, 40, 879-889.	5.9	2
34	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	1.6	17
35	Characterization of Underrepresented Populations in Modern Era Clinical Trials Involving Radiation Therapy. Practical Radiation Oncology, 2021, 11, 453-459.	2.1	7
36	Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. , $2021,  ,  .$		0

#	Article	lF	Citations
37	Opportunities and Challenges of Genomically Guided Decision Making for Patients With Prostate Cancer. Practical Radiation Oncology, 2020, 10, 93-94.	2.1	O
38	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. Journal of Gastrointestinal Surgery, 2020, 24, 235-242.	1.7	6
39	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	3.0	2
40	ADC measurements on the Unity MR-linac – A recommendation on behalf of the Elekta Unity MR-linac consortium. Radiotherapy and Oncology, 2020, 153, 106-113.	0.6	60
41	Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac. PLoS ONE, 2020, 15, e0236570.	2.5	49
42	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in Oncology, 2020, 10, 1328.	2.8	81
43	Cytokines, JAK-STAT Signaling and Radiation-Induced DNA Repair in Solid Tumors: Novel Opportunities for Radiation Therapy. International Journal of Biochemistry and Cell Biology, 2020, 127, 105827.	2.8	6
44	A Patient-Specific Autosegmentation Strategy Using Multi-Input Deformable Image Registration for Magnetic Resonance Imaging–Guided Online Adaptive RadiationÂTherapy: A Feasibility Study. Advances in Radiation Oncology, 2020, 5, 1350-1358.	1.2	26
45	4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience. Clinical and Translational Radiation Oncology, 2020, 23, 72-79.	1.7	71
46	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncology, 2020, 6, 735.	7.1	58
47	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Practical Radiation Oncology, 2020, 10, e495-e507.	2.1	50
48	Auto-segmentation of pancreatic tumor in multi-parametric MRI using deep convolutional neural networks. Radiotherapy and Oncology, 2020, 145, 193-200.	0.6	61
49	MRI-Based Upper Abdominal Organs-at-Risk Atlas for Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 106, 743-753.	0.8	21
50	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 460.	2.8	20
51	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Hpb, 2020, 22, 1745-1752.	0.3	2
52	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiation Oncology, 2019, 14, 114.	2.7	34
53	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery, 2019, 166, 277-285.	1.9	40
54	The transformation of radiation oncology using real-time magnetic resonance guidance: A review. European Journal of Cancer, 2019, 122, 42-52.	2.8	136

#	Article	IF	CITATIONS
55	A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. Npj Precision Oncology, 2019, 3, 25.	5.4	98
56	Estimation of changing gross tumor volume from longitudinal CTs during radiation therapy delivery based on a texture analysis with classifier algorithms: a proof-of-concept study. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1189-1200.	2.0	0
57	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2019, 9, 322-332.	2.1	121
58	Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiotherapy and Oncology, 2019, 141, 137-143.	0.6	8
59	Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. JAMA Oncology, 2019, 5, 664.	7.1	40
60	A preferred patient decubitus positioning for magnetic resonance image guided online adaptive radiation therapy of pancreatic cancer. Physics and Imaging in Radiation Oncology, 2019, 12, 22-29.	2.9	1
61	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery, 2019, 84, 66-76.	1.1	7
62	Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9. Frontiers in Oncology, 2019, 9, 1464.	2.8	38
63	Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer. Cureus, 2019, 11, e4510.	0.5	10
64	Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review. Neurosurgery, 2018, 82, 595-603.	1.1	9
65	Pancreatic gross tumor volume contouring on computed tomography (CT) compared with magnetic resonance imaging (MRI): Results of an international contouring conference. Practical Radiation Oncology, 2018, 8, 107-115.	2.1	19
66	Locally advanced pancreas cancer: Staging and goals of therapy. Surgery, 2018, 163, 1053-1062.	1.9	53
67	Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. Journal of the National Cancer Institute, 2018, 110, 460-466.	6.3	17
68	Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer. Translational Oncology, 2018, 11, 391-398.	3.7	34
69	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101, 274-284.	0.8	50
70	The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. Abdominal Radiology, 2018, 43, 393-403.	2.1	6
71	2555 Predictive cytological topography (PiCT): A radiopathomics approach to mapping prostate cancer. Journal of Clinical and Translational Science, 2018, 2, 23-24.	0.6	0
72	Variations of MRI-assessed peristaltic motions during radiation therapy. PLoS ONE, 2018, 13, e0205917.	2.5	32

#	Article	IF	CITATIONS
73	A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2018, 268, 610-619.	4.2	58
74	Imaging predictors of treatment outcomes in rectal cancer: An overview. Critical Reviews in Oncology/Hematology, 2018, 129, 153-162.	4.4	17
75	Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1179-1187.	0.8	49
76	Rectal cancer patients younger than 50 years lack a survival benefit from <scp>NCCN</scp> guideline–directed treatment for stage <scp>II</scp> and <scp>III</scp> disease. Cancer, 2018, 124, 3510-3519.	4.1	68
77	PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study. Translational Oncology, 2018, 11, 1104-1109.	3.7	20
78	Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer, 2017, 123, 3486-3493.	4.1	103
79	Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. Practical Radiation Oncology, 2017, 7, e449-e455.	2.1	0
80	Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. Seminars in Radiation Oncology, 2017, 27, 11-20.	2.2	8
81	Considerations Regarding the Role of Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma in the Elderly. Journal of Oncology Practice, 2017, 13, 171-172.	2.5	0
82	Adaptive radiation dose escalation in rectal adenocarcinoma: a review. Journal of Gastrointestinal Oncology, 2017, 8, 902-914.	1.4	18
83	Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. Journal of Medical Imaging, 2017, 5, 1.	1.5	30
84	Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS ONE, 2017, 12, e0178961.	2.5	62
85	TNFRSF10C copy number variation is associated with metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2016, 7, 306-314.	1.4	14
86	Cholangiocarcinoma size on magnetic resonance imaging versus pathologic specimen: Implications for radiation treatment planning. Practical Radiation Oncology, 2016, 6, 201-206.	2.1	1
87	Lymph node ratio influence on risk of head and neck cancer locoregional recurrence after initial surgical resection: Implications for adjuvant therapy. Head and Neck, 2015, 37, 777-782.	2.0	64
88	Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. Journal of Gastrointestinal Oncology, 2015, 6, 247-53.	1.4	2
89	CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer. Cancer Research, 2014, 74, 2677-2687.	0.9	34
90	Accuracy of Computed Tomography for Predicting Pathologic Nodal Extracapsular Extension in Patients With Head-and-Neck Cancer Undergoing Initial Surgical Resection. International Journal of Radiation Oncology Biology Physics, 2014, 88, 122-129.	0.8	92

#	Article	IF	CITATIONS
91	Similar Survival for Patients Undergoing Reduced-Intensity Total Body Irradiation (TBI) Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia. International Journal of Radiation Oncology Biology Physics, 2014, 89, 360-369.	0.8	7
92	The management of adenocarcinoma of the prostate in rural Georgia: A population-based analysis Journal of Clinical Oncology, 2014, 32, 273-273.	1.6	0
93	The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 77-85.	1.4	10
94	Treatment Efficiency of Volumetric Modulated Arc Therapy in Comparison With Intensity-Modulated Radiotherapy in the Treatment of Prostate Cancer. Journal of the American College of Radiology, 2013, 10, 128-134.	1.8	16
95	Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate. Practical Radiation Oncology, 2013, 3, e157-e164.	2.1	10
96	Tumor Size on Abdominal MRI Versus Pathologic Specimen in Resected Pancreatic Adenocarcinoma: Implications for Radiation Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2013, 86, 102-107.	0.8	35
97	The association between Câ€reactive protein (CRP) level and biochemical failureâ€free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. Cancer, 2013, 119, 3272-3279.	4.1	35
98	The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer, 2013, 119, 2350-2357.	4.1	13
99	Radiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base: A multi-institutional comparative analysis Journal of Clinical Oncology, 2013, 31, 305-305.	1.6	0
100	Comparing central nervous system (CNS) and extraâ€CNS hemangiopericytomas in the Surveillance, Epidemiology, and End Results program. Cancer, 2012, 118, 5331-5338.	4.1	12
101	Stereotactic Body Radiosurgery for Spinal Metastatic Disease: An Evidence-Based Review. International Journal of Surgical Oncology, 2011, 2011, 1-9.	0.6	32